AFM
ASMB icon

Anson Funds Management’s Assembly Biosciences ASMB Stock Holding History

Anson Funds Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-59,956
Closed -$590K – 156
2023
Q4 		$590K Buy
+59,956
New +$570K 0.07% 122
2022
Q1 		– Sell
-14,933
Closed -$418K – 345
2021
Q4 		$418K Buy
+14,933
New +$490K 0.04% 257

Other funds holding ASMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Anson Funds Management's ASMB Position: Q1 2024 in Review

Anson Funds Management sold out of Assembly Biosciences (ASMB) in Q1 2024, closing a stake of 59,956 shares — an estimated $590K sold.

Anson Funds Management first reported a position in ASMB in Q4 2021 and held it in 2 quarters. The position peaked at $590K in Q4 2023. 24 funds tracked by Wall St. Rank hold ASMB as of Q1 2024.

  • Anson Funds Management reported no remaining Assembly Biosciences position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 59,956 Assembly Biosciences shares in Q1 2024, an estimated $590K.
  • Anson Funds Management first reported a position in Assembly Biosciences in Q4 2021 and held it in 2 quarters.
  • Anson Funds Management's Assembly Biosciences position peaked at $590K in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.